TransMedics Group, Inc. (TMDX) P/E Ratio History
UndervaluedTrading at 24.9x vs 5Y avg 424.6x · 30th percentile · Below historical baseline · Data 2024–2026
Loading P/E history...
P/E Ratio Analysis
As of November 8, 2026, TransMedics Group, Inc. (TMDX) trades at a price-to-earnings ratio of 24.9x, with a stock price of $88.24 and trailing twelve-month earnings per share of $3.54.
The current P/E is 94% below its 5-year average of 424.6x. Over the past five years, TMDX's P/E has ranged from a low of 17.2x to a high of 3765.5x, placing the current valuation at the 30th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.6x, TMDX is roughly in line with its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 196.0x.
Relative to the broader market, TMDX trades roughly in line with the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TMDX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
TMDX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
TMDX P/E vs Peers
Cardiovascular, Renal & Blood Devices peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 23.8 | 2.01 | +14% | |
| $5B | 26.3 | - | -484% | |
| $3B | 196.0 | - | +75%Best | |
| $5B | 32.9 | - | +5% | |
| $4B | 42.2 | 9.59 | -15% | |
| $358B | 22.4 | - | -15% | |
| $12B | 13.6Lowest | 1.65Best | -11% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
TMDX Historical P/E Data (2024–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q3 | Sep 30 2026 | $83.45 | $3.66 | 22.8x | -95% |
| FY2026 Q2 | - | $66.42 | $3.86 | 17.2x | -96% |
| FY2026 Q1 | - | $99.41 | $4.37 | 22.7x | -95% |
| FY2025 Q4 | Dec 31 2025 | $121.65 | $4.87 | 25.0x | -94% |
| FY2025 Q3 | - | $112.20 | $2.47 | 45.4x | -89% |
| FY2025 Q2 | Jun 30 2025 | $134.01 | $1.93 | 69.4x | -84% |
| FY2025 Q1 | Mar 31 2025 | $67.28 | $1.36 | 49.5x | -88% |
| FY2024 Q4 | - | $62.35 | $1.01 | 61.7x | -85% |
| FY2024 Q3 | Sep 30 2024 | $157.00 | $0.94 | 167.0x | -61% |
| FY2024 Q2 | Jun 30 2024 | $150.62 | $0.04 | 3765.5x | +787% |
Average P/E for displayed period: 424.6x
TMDX Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
2+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TMDX — Frequently Asked Questions
Quick answers to the most common questions about buying TMDX stock.
What is TMDX's P/E ratio?
TransMedics Group, Inc. (TMDX) trailing twelve-month P/E ratio is 24.9x, based on TTM diluted EPS of $3.54. The 5-year average P/E is 424.6x and the historical range spans 17.2x to 3765.5x.
Is TMDX stock overvalued or undervalued?
TMDX trades at 24.9x P/E, below its 5-year average of 424.6x. At the 30th percentile of its historical range (17.2x–3765.5x), the stock is priced at a discount to its own history.
Is TMDX stock expensive?
No, TMDX is not expensive on a historical basis. The current P/E of 24.9x is below the 5-year average of 424.6x and sits at the 30th percentile of its valuation range.
What is TMDX's historical P/E range?
Over the past 5 years, TMDX's P/E ratio has ranged from 17.2x to 3765.5x, with a median of 49.5x and an average of 424.6x. The current P/E of 24.9x places the stock at the 30th percentile of this range. Full historical data spans 2024–2026.
How does TMDX's P/E compare to the S&P 500?
TMDX trades at 24.9x P/E versus the S&P 500 median of 21.8x. The 14% premium to the market typically reflects higher expected earnings growth or quality.
How does TMDX's valuation compare to Healthcare peers?
TransMedics Group, Inc. P/E of 24.9x compares to the Healthcare sector median of 24.6x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is TMDX's PEG ratio?
TMDX PEG ratio is N/A, based on a P/E of 24.9x and EPS growth of 382.2%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is TMDX's earnings yield?
TMDX earnings yield is 4.01%, the inverse of its 24.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.